248 related articles for article (PubMed ID: 36872338)
1. Fracture risk in women with osteoporosis initiated on gastro-resistant risedronate versus immediate release risedronate or alendronate: a claims data analysis in the USA.
Eisman JA; Cortet B; Boolell M; Ionescu-Ittu R; Vekeman F; Heroux J; Thomasius F
Osteoporos Int; 2023 May; 34(5):977-991. PubMed ID: 36872338
[TBL] [Abstract][Full Text] [Related]
2. Fracture rates and economic outcomes in patients with osteoporosis prescribed risedronate gastro-resistant versus other oral bisphosphonates: a claims data analysis.
Thomasius F; Palacios S; Alam A; Boolell M; Vekeman F; Gauthier G
Osteoporos Int; 2022 Jan; 33(1):217-228. PubMed ID: 34490504
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of gastro-resistant risedronate tablets for the treatment of postmenopausal women with osteoporosis in France.
Hiligsmann M; Reginster JY
Osteoporos Int; 2019 Mar; 30(3):649-658. PubMed ID: 30701342
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of risedronate and alendronate on nonvertebral fractures: an observational study through 2 years of therapy.
Lindsay R; Watts NB; Lange JL; Delmas PD; Silverman SL
Osteoporos Int; 2013 Aug; 24(8):2345-52. PubMed ID: 23612793
[TBL] [Abstract][Full Text] [Related]
5. Longitudinal change in clinical fracture incidence after initiation of bisphosphonates.
Abelson A; Ringe JD; Gold DT; Lange JL; Thomas T
Osteoporos Int; 2010 Jun; 21(6):1021-9. PubMed ID: 19722103
[TBL] [Abstract][Full Text] [Related]
6. Oral bisphosphonates reduce the risk of clinical fractures in glucocorticoid-induced osteoporosis in clinical practice.
Thomas T; Horlait S; Ringe JD; Abelson A; Gold DT; Atlan P; Lange JL
Osteoporos Int; 2013 Jan; 24(1):263-9. PubMed ID: 22736069
[TBL] [Abstract][Full Text] [Related]
7. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
Stevenson M; Jones ML; De Nigris E; Brewer N; Davis S; Oakley J
Health Technol Assess; 2005 Jun; 9(22):1-160. PubMed ID: 15929857
[TBL] [Abstract][Full Text] [Related]
8. Incidence of fractures of the femur, including subtrochanteric, up to 8 years since initiation of oral bisphosphonate therapy: a register-based cohort study using the US MarketScan claims databases.
Pazianas M; Abrahamsen B; Wang Y; Russell RG
Osteoporos Int; 2012 Dec; 23(12):2873-84. PubMed ID: 22431012
[TBL] [Abstract][Full Text] [Related]
9. Differences in persistence among different weekly oral bisphosphonate medications.
Sheehy O; Kindundu CM; Barbeau M; LeLorier J
Osteoporos Int; 2009 Aug; 20(8):1369-76. PubMed ID: 19020921
[TBL] [Abstract][Full Text] [Related]
10. Analysis of the comparative effectiveness of 3 oral bisphosphonates in a large managed care organization: adherence, fracture rates, and all-cause cost.
Martin KE; Yu J; Campbell HE; Abarca J; White TJ
J Manag Care Pharm; 2011 Oct; 17(8):596-609. PubMed ID: 21942301
[TBL] [Abstract][Full Text] [Related]
11. Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations.
Tosteson AN; Burge RT; Marshall DA; Lindsay R
Am J Manag Care; 2008 Sep; 14(9):605-15. PubMed ID: 18778176
[TBL] [Abstract][Full Text] [Related]
12. Aging bone and osteoporosis: strategies for preventing fractures in the elderly.
Ettinger MP
Arch Intern Med; 2003 Oct; 163(18):2237-46. PubMed ID: 14557222
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
Iwamoto J; Takeda T; Sato Y
Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
[TBL] [Abstract][Full Text] [Related]
14. Risedronate versus alendronate in older patients with osteoporosis at high risk of fracture: an Italian cost-effectiveness analysis.
Berto P; Maggi S; Noale M; Lopatriello S
Aging Clin Exp Res; 2010 Apr; 22(2):179-88. PubMed ID: 20145427
[TBL] [Abstract][Full Text] [Related]
15. Risedronate: a new oral bisphosphonate.
Umland EM; Boyce EG
Clin Ther; 2001 Sep; 23(9):1409-21. PubMed ID: 11589256
[TBL] [Abstract][Full Text] [Related]
16. Persistance and Compliance with Osteroporosis Therapies Among Women in a Commercially Insured Population in the United States.
Cheng LI; Durden E; Limone B; Radbill L; Juneau PL; Spangler L; Mirza FM; Stolshek BS
J Manag Care Spec Pharm; 2015 Sep; 21(9):824-33, 833a. PubMed ID: 26308229
[TBL] [Abstract][Full Text] [Related]
17. Comparison of risedronate to alendronate and calcitonin for early reduction of nonvertebral fracture risk: results from a managed care administrative claims database.
Watts NB; Worley K; Solis A; Doyle J; Sheer R
J Manag Care Pharm; 2004; 10(2):142-51. PubMed ID: 15032563
[TBL] [Abstract][Full Text] [Related]
18. Hip fractures in users of first- vs. second-generation bisphosphonates.
Mamdani M; Kopp A; Hawker G
Osteoporos Int; 2007 Dec; 18(12):1595-600. PubMed ID: 17767369
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study.
Silverman SL; Watts NB; Delmas PD; Lange JL; Lindsay R
Osteoporos Int; 2007 Jan; 18(1):25-34. PubMed ID: 17106785
[TBL] [Abstract][Full Text] [Related]
20. RisedronatE and ALendronate Intervention over Three Years (REALITY): minimal differences in fracture risk reduction.
Curtis JR; Westfall AO; Cheng H; Saag KG; Delzell E
Osteoporos Int; 2009 Jun; 20(6):973-8. PubMed ID: 18946630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
